'All Options On The Table,' Says Hillebrenner On Diagnostics Reform
Executive Summary
During a recent webinar hosted by the Alliance for a Stronger FDA, Elizabeth Hillebrenner, associate director for scientific and regulatory programs at the agency’s device center, vowed to keep fighting for diagnostic reform despite Congress failing to pass the VALID Act last year.
You may also be interested in...
Harbinger Health CEO Stephen Hahn On Early Cancer Detection To ‘Move The Needle’ On Survival
Medtech Insight spoke with Stephen Hahn, ex-FDA commissioner and CEO of Harbinger Health, who attended SXSW, about the firm’s blood-based cancer test in development.
FDA FY 2024 Budget Includes 10% Funding Boost, But No Movement On Diagnostics
The FDA requested a 10% increase in budget authority for FY 2024, but diagnostic reform was left out of the proposal.
Califf Sits Down For Fireside Chat; Looks Back And Ahead
Robert Califf marked his one-year anniversary as the commissioner of the US Food and Drug Administration by discussing the first year of his second term as the agency’s chief executive and his vision for the future.